Abstract:Genetically engineered T cells therapy is a promising strategy in cancer immunotherapy. Chimeric antigen receptor (CAR)-T cells therapy, as one successful strategy, has achieved the breakthrough and been approved in non-solid tumor but not solid tumor, which might be limited partially by CARs-restricted on cell surface and side effects of retrovirus. Meanwhile, bispecific T cell engager (BiTE), as another successful strategy, has been approved in non-solid tumor, the therapeutic limitation of which in solid tumor might be the short half-life of antibodies, the lack of endogenous effector T cells in patients with advanced cancer, and severe adverse effects. In this study, we developed a novel glypican-3 (GPC3)-targeting BiTE, αGPC3/CD3. These GPC3-BiTE engineered human T cells persistently produced GPC3-BiTE fusion proteins, which were released extracellularly to help both engineered T cell and bystander T cells to exhibit GPC3-specific activity. As a result, GPC3-BiTE-T cells could possess the capability of both CAR-T cells and BiTE, and even aid more than conventional CART cells in the CART-like function. In addition, GPC3+ tumor-bearing mice treated with the secretable GPC3-BiTE-T cells got a significant tumor growth inhibition and prolonged survival without observed adverse effect. Compared with control groups, more GPC3-BiTE-T cells with less PD-1 expression were detected at tumor site, which was similar to the GPC3-CART cell therapy. And the accumulation of GPC3-BiTE-T cells was positively related with the inhibition of tumor growth. Moreover, GPC3-BiTE-T cells assisted bystander T cells accumulated into tumor site in vivo, which was lack in GPC3-CART cell therapy. Thus, the novel GPC3-BiTE-T cells have the characteristics of high potency, long term and low toxicity, which might supply an attractive GPC3-targeting immunotherapy for solid tumors.Citation Format: Feifei Luo, Yuedi Wang, Jie Liu, Yiwei Chu. BiTE-T cell: A novel design for solid tumor [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 2328.

Abstract 2328: BiTE-T Cell: A Novel Design for Solid Tumor